Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University. “Mr. Dorman is one of the remarkable icons in the healthcare industry and we are thrilled to have him join our Board,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, “Paul’s experience and network in both the large and small pharma world, as well as his wisdom in leading companies to success, will be major contributing factors to the RXi Board of Directors and the growth of our Company.”

Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. Most recently, he has been an Independent Pharmaceutical & Life Sciences Consultant for OPKO Health, Inc. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO's R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. “Dr. Lockshin has an impressive career track record in research and development of new drugs”, commented Dr. Geert Cauwenbergh. “With RXi Pharmaceuticals in the midst of a game changing drug in development with RXI-109 for dermal scarring, Curt will provide valuable insights into the development of our drugs. With Paul Dorman and Curt Lockshin joining our current Board members Bob Bitterman and Keith Brownlie, RXi Pharmaceuticals has a well rounded Board of Directors with an appropriate balance of all key elements needed for success.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising New Data on Self-delivering RNAi Compounds
RXi Pharmaceuticals Corporation have presented new data, on the company's proprietary self-delivering RNAi compounds developed to target Tyrosinase (TYR) and Collagenase (MMP1).
Wednesday, May 13, 2015
RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement
Agreement for RXI-109 in the European Union under the “Specials” Provision.
Tuesday, November 19, 2013
RXi Pharmaceuticals Awarded NCI SBIR Funding
Company awarded approximately $300,000 to advance self-delivering RNAi technology.
Friday, October 12, 2012
RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
The collaboration will evaluate the potential utility of RXi’s rxRNA™ technology against specific miRNA targets of interest to mirage.
Tuesday, April 13, 2010
RXi Acquires Exclusive License to Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC
The in-licensed technologies encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics.
Wednesday, July 29, 2009
RXi Pharmaceuticals Presented Breakthrough RNAi Delivery Technologies at the TIDES® 2009 Conference
Company’s CSO, Anastasia Khvorova, presented new pre-clinical data on therapeutically advanced RNAi compounds and delivery technologies.
Monday, May 25, 2009
RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
Company plans to advance the discovery and development Oral rxRNA™ therapeutics for inflammatory diseases.
Wednesday, February 11, 2009
RXi Pharmaceuticals Licenses RNA Chemistry Technologies from TriLink Biotechnologies
The agreement includes rights to sublicense a patented RNA linker technology, a patent application on RNAi compositions and an undisclosed chemistry approach.
Tuesday, September 11, 2007
Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!